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Abstract 
A cDNA clone for mouse pituitary adenylate cyclase-activating polypeptide (PACAP) receptor (PACAP-R) was obtained from the 
brain using reverse transcription-polymerase chain reaction (RT-PCR). The recombinant PACAP receptor expressed in COS cells bound 
PACAP with about 1000-times higher affinity than vasoactive intestinal polypeptide (VIP), and PACAP stimulated adenylate cyclase 
through the cloned PACAP receptor. The mouse PACAP receptor consists of 496 amino acids, contains even transmembrane segments 
and has 98.4%, 93.0%, and 92.5% identity with the rat, bovine, and human PACAP-R, respectively. 
Keywords: Pituitary adenylate cyclase-activating polypeptide receptor; PACAP receptor; cDNA cloning; Vasoactive intestinal polypeptide; (Mouse) 
PACAP is a member of the vasoactive intestinal 
polypeptide (VIP)/secretin/glucagon family [1]. PACAP 
has a variety of biological actions: it stimulates neurite- 
outgrowth of sympathetic neuroblast and PC-12 cells [2,3], 
increases the release of acetylcholine from the hippocam- 
pus [4], catecholamines from adrenal chromaffin cells [5], 
insulin from the pancreas [6], melatonin from pinealocytes 
[7]. These diverse biological actions of PACAP are medi- 
ated by two types of high-affinity PACAP-R [1-3]: both 
PACAP and VIP bind to the type II receptor with similar 
affinity, while PACAP shows 100-1000-times higher 
affinity than VIP to the type I receptor. The rat VIPI 
receptor cloned by Ishihara et al. showed similar affinity to 
both PACAP and VIP, indicating that it was the type lI 
receptor [8]. Recently, several groups, including ours, have 
cloned the rat type I PACAP-preferring receptor (PACAP- 
R) [9-13]. Another subtype of the type II receptors, VIP2 
receptor, has also been cloned [14,15]. 
More recently, we have isolated the mouse PACAP-R 
gene and determined its structural organization [16]. In this 
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study, we obtained a cDNA clone encoding the mouse 
PACAP-R using RT-PCR. Here we present he nucleotide 
sequence of the mouse PACAP-R and the properties of the 
receptor expressed in COS cells transfected with the cDNA. 
PACAP (Human PACAP-38) and VIP were purchased 
from the Peptide Institute (Osaka, Japan). [125I]PACAP 
([l:5I]PACAP-27, 2200 Ci/mmol) was obtained from 
NEN. Total cellular RNA was prepared from the brain of 
8-week-old male DDY mouse, and poly(A)-containing 
RNA was enriched and transcribed into random-primed, 
single-stranded cDNA as described [9]. A set of oligo- 
nucleotides of 20-mer containing sequences for the exons 
1 and 16 of the mouse PACAP-R gene [16] (exon 1: 
5'-ATTCGCGGGTTGCGCGTCCT-3' for the forward 
primer and exon 16: 5'-TCAGGTGGCCAAGTTGTCGG-3' 
for the reverse primer) was synthesized. The PCR was 
performed using Taq DNA polymerase and Taq Extender 
PCR Additive (Stratagene) according to the following 
schedule: 35 cycles of denaturation at 94°C for 1 min, 
annealing at 58°C for 2 min, and extension at 72°C for 3 
rain. The PCR products were subcloned into pBluescript 
and sequenced. Clone 17 was selected and further sub- 
cloned into the eukaryotic expression vector, pEF-BOS 
[17] to generate pCAPMI7. Transfection of the cDNA to 
COS7 cells, preparation of membrane fractions, binding 
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study of []~I]PACAP, and cAMP assay were performed as 
described previously [9]. 
The nucleotide sequence and the predicted amino acid 
sequence of pCAPM17 were shown in Fig. 1A. The 
nucleotide sequence of pCAPM17 matched the genomic 






ATG GCC AGA ACC CTG CAG CTC TCC CTG ACT GCT CTC CTC CTG CTG CCT ATG GCT ATT GCT ATG CAC TCT 
Met Ala Arg Thr Leu Gln Leu Ser Leu Thr Ala Leu Leu Leu Leu Pro Met Ala Ile Ala Met His Ser 
-20  -1  1 
GAC TGC ATC TTC AAG AAG GAG CAA GCC ATG TGC CTG GAG AGG ATC CAG AGG GCC AAC GAC CTG ATG GGC 
Asp Cys Ile Phe Lys Lys Glu Gln Ala Met Cys Leu Glu Arg Ile Gln Arg Ala Ash Asp Leu Met Gly 
CTA AAT GAG TCT TCC CCA GGT TGC CCT GGC ATG TGG GAC AAT ATe ACA TGT TGG AAG CCT GCT CAA ATA 
Leu A~n Glu Ser Ser Pro Gly Cys Pro Gly Met Trp Asp A~n Ile Thr Cys Trp Lys Pro Ala Gln Ile 
40O 
GGT GAG ATG GTC CTT GTG AGC TGC CCT GAG GTC TTC eGG ATC TTC AAC CCG GAC CAA GTC TGG ATG ACA 
Gly Glu Met Val Leu Val Ser Cys Pro Glu Val Phe Arg Ile Phe Asn Pro Asp Gln Val Trp Met Thr 
50  
GAA ACC ATA GGG GAT TCT GGC TTT GCT GAT AGT AAT TCC TTG GAG ATC ACA GAC ATG GGG GTC GTG GGC 
Glu Thr Ile Gly Asp Ser Gly Phe Ala Asp Ser Asn Ser Leu Glu Ile Thr Asp Met Gly Val Val Gly 
CGG AAC TGC ACT GAG GAT GGC TGG TCG GAG CCC TTC CCC CAT TAC TTC GAT GCT TGT GGG TTT GAT GAC 
Arg A@n Cys Thr Glu Asp Gly Trp Ser Glu Pro Phe Pro His Tyr Phe Asp Ala Cys Gly Phe Asp Asp 
i00  
6O0 
TAT GAG CCC GAG TCT GGG GAT CAG GAT TAT TAC TAC CTG TCG GTG AAG GCC CTC TAC ACA GTC GGC TAC 
Tyr Glu Pro Glu Ser Gly Asp Gln Asp Tyr Tyr Tyr Leu Ser Val Lys Ala Leu Tyr Thr Val Gly Tyr 
I 
AGC ACC TCC CTC GTC ACC CTC ACC ACT GCC ATG GTC ATC TTG TGC CGC TTC CGG AAG CTG CAC TGT ACC 
Ser Thr Ser Leu Val Thr Leu Thr Thr Ala Met Val Ile Leu Cys Arq Phe Arg Lys Leu His Cys Thr 
15o  
CGT AAC TTC ATC CAC ATG AAC CTG TTT GTA TCC TTC ATG CTG AGA GCT ATC TCT GTC TTC ATC AAA GAC 
Arg ASh Phe Ile His Met Asn Leu Phe Val Ser Phe Met Leu Arq Ala Ile Ser Val Phe Ile Lys Asp 
I I  
8OO 
TGG ATC TTG TAT GCC GAG CAG GAC AGC AGT CAT TGC TTC GTT TCC ACC GTG GAA TGC AAA GCT GTC ATG 
Trp Ile Leu Tyr Ala GIu Gln Asp Ser Ser His Cys Phe Val Ser Thr Val Glu Cys Lys Ala Val Met 
200 I T I  
GTT TTC TTT CAC TAC TGC GTG GTG TCC AAC TAC TTC TGG CTG TTC ATT GAA GGC CTA TAC CTC TTT ACA 
Val Phe Phe His Tyr Cys Val Val Ser Asn Tyr Phe Trp Leu Phe Ile Glu GIy Leu Tyr Leu Phe Thr 
CTG CTG GTG GAG ACC TTC TTC CCT GAG AGG AGA TAT TTC TAC TGG TAT ACC ATC ATT GGC TGG GGG ACA 
Leu Leu Val Glu Thr Phe Phe Pro Glu Arg Arg Tyr Phe Tyr Trp Tyr Thr Ile Ile GIy Trp Gly Thr 
250 IV  
i000 
CCT ACT GTG TGT GTA ACT GTG TGG GCT GTG CTG AGG CTC TAC TTT GAT GAT GCG GGA TGC TGG GAT ATG 
Pro Thr Val Cvs Val Thr Val TrD Ala Val Leu Arg Leu Tyr Phe Asp Asp Ala Gly Cys Trp Asp Met 
AAT GAC AGC ACA GCT CTG TGG TGG GTG ATC AAA GGC CCT GTA GTT GGC TCT ATA ATG GTT AAC TTT GTG 
A~n Asp Set Thr Ala Leu Tip Trp Val Ile Lys Giy Pro Val Val GIy Ser Ile Met Val Asn Phe Val 
V 300 
CTT TTC ATC GGC ATC ATC ATC ATC CTT GTG CAG AAG CTG CAG TCC CCA GAC ATG GGA GGC AAT GAG TCG 
Leu Phe Ile Giy Ile Ile Ile Ile Leu Val Gln Lys Leu Gln Ser Pro Asp Met Gly Gly Asn Glu Ser 
1200 
AGC ATC TAC TTC-AC~C-T~C~GT~-CAC~-AAA-TGC--TAC-TGC~%C~-CCA-~AG-~C~C~-GC~-~AG-CAG~cAC-T~-TC:&~-~A~ 
ATG_~CA_ I?~_~T~_~CC_ACC_ATT_ACT_~TA CGG CTG GCC CGC TCC ACC CTG CTG CTC ATC CCA CTC TTT GGA 
~--se~--6ih--L~h--~e~--#h~--ii~--~--£eh Arg Leu Ala Arg Ser Thr Leu Leu Leu Ile Pro Leu Phe Giy 
350 vx  
ATC CAC TAC ACA GTA TTT GCC TTC TCT CCA GAG AAC GTC AGC AAG AGG GAA AGA CTT GTG TTT GAG CTT 
Ile His Tyr Thr Val Phe Ala Phe Ser Pro Glu A~n Val Ser Lys Arg Glu Arg Leu Val Phe Glu Leu 
v i i  
1400 
GGG CTG GGC TCC TTC CAG GGC TTT GTG GTG GCT GTA CTC TAC TGC TTC CTG A_AT GGG GAG GTA CAG GCA 
GIy Leu GIy Ser Phe Gln Gly Phe Val Val Ala Val Leu Tyr Cys Phe Leu Asn Gly Glu Val Gln Ala 
400 
GAG ATT AAG AGG AAA TGG AGG AGC TGG AAG GTG AAC CGT TAc TTC ACT ATG GAC TTC AAG CAC CGG CAT 
Glu Ile Lys Arg Lys Trp Arg Ser Trp Lys Val Asn Arg Tyr Phe Thr Met Asp Phe Lys His Arg His 
1600 
CCA TCC CTG GCC AGC AGT GGA GTG AAC GGG GGC ACC CAG CTG TCC ATC CTG AGC AAG AGC AGC TCC CAG 
Pro Ser Leu Ala Ser Ser Gly Val Asn Gly Gly Thr Gln Leu Ser Ile Leu Ser Lys Ser Ser Ser Gln 
450  
1644 
CTC CGC ATG TCC AGC CTC CCG GCC GAC AAC TTG GCC ACC TGA 
Leu Arg Met Ser Ser Leu Pro Ala Asp Asn Leu Ala Thr End 
476 
H. Hashimoto et al. / Biochimica et Biophysica Acta 1281 (1996) 129-133 131 
gene (data not shown). The neighboring sequence of the 
potential AUG initiation codon agrees well with the con- 
sensus equence proposed by Kozak [18]. pCAPM17 cDNA 
contains an open reading frame coding for a protein of 496 
amino acids. The first N-terminal 20 amino acids seem to 
serve as a signal sequence [19]. The mature mouse 
PACAP-R protein, thus, consists of 476 amino acids with 
a calculated molecular mass of 54523. The hydropathy 
analysis of the PACAP-R indicated that it contains 7 
transmembrane regions (shown by I-VII in Fig. 1A). In 
the predicted extracellular regions, there are 5 potential 
N-glycosylation sites (Asn-X-Thr/Ser) (Fig. 1A). It has 
been reported that the rat PACAP-R consists from several 
isoforms with one or two insertions at the third intra- 
cellular loop [13]. The two alternative xons (Hip and 
Hop) corresponding to these insertion sequences have been 
found in the mouse PACAP-R gene [16]. The receptor that 
was encoded by pCAPM17 had the 84 bp insertion 
(nucleotides from 1200 to 1283 in Fig. I A) which were 
derived from the exon Hop. The expression of three other 
forms of the splicing variants of the mouse PACAP-R was 
confirmed by RT-PCR and nucleotide sequencing analysis 
(Fig. 1B). 
As shown in Fig. 2, the deduced amino acid sequence 
of the mouse PACAP-R showed high overall sequence 
homology to the rat [9-13], bovine [20], and human 
PACAP-R [21] (98.4%, 93.0%, and 92.5%, respectively) 
(the human PACAP-R was compared with the mouse 
PACAP-R lacking a 28 amino acid portion derived from 
the exon Hop). Five potential N-glycosylation sites were 
conserved among the four receptors, except for that of the 
second extracellular loop of the bovine receptor. The extra- 
cellular egion of members of this receptor family contains 
highly conserved cysteine and tryptophan residues [9]. 
These were also conserved in the mouse PACAP-R (Fig. 
2). 
Transfection of the cDNA into COS7 cells conferred on 
them high affinity binding of [~25I]PACAP (Fig. 3A). The 
membranes from mock-transfected cells did not show any 
significant binding of [125I]PACAP (data not shown). 
Competitive binding experiments revealed that PACAP 
potently displaced [125I]PACAP binding (IC50 = 0.2 nM) 
while VIP was about 1000-times less potent han PACAP 
(IC50 > 1 ;zM). To examine whether the cloned receptor 
transduces the signals, the accumulation of cAMP in the 
COS7 cells expressing the PACAP-R was quantified. As 
shown in Fig. 3B, PACAP markedly stimulated the accu- 
mulation of cAMP in the cells (ECs0 = 0.3 nM). In accor- 
dance with the weak binding activity of VIP to the 
PACAP-R, it stimulated cAMP accumulation atconcentra- 
tions higher than 10 nM. These results indicate that the 
cloned PACAP-R cDNA encodes the PACAP-R (type I 
receptor). 
In conclusion, we have cloned and expressed a mouse 
PACAP-R cDNA. The cDNA clone isolated in this study 
will be useful for the study such as in situ hybridization 
and ribonuclease protection assay in mice. 

















. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  ACGGCTGGCC 
uArgLeuAla 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  ACGGCTGGCC 
uArgLeuAla 
CAGCTGCGTGCAGAAATG•TACTGCAAGCCACAGCGGGCTCAGCAGCA•TCTTGCAAGATGTCAGAACTATCcACCATTACT•TACGGCTGGCC 
eSerCysValGlnLys CysTyrCysLys ProGlnArgAl aGlnGlnHi sSerCysLysMe t SerGluLeuSerThr I i eThrLeuArgLeuAla 
CAGCTGCGTGCAGAAATGCTACTGCAAGCCACAGCGGGCTCAGCAGCACTCTTGCAAGATGTCAGAACTATCCACCATTACTCTACGGCTGGCC 
uSerCysValGl nLysCysTyrCysLys ProGlnArgAl aGlnGlnHisSerCysLysMet SerGluLeuSerThr I i eThrLeuArgLeuAl a 
Fig. 1. Sequence of the mouse pituitary adenylate cyclase-activating polypeptide (PACAP) receptor (PACAP-R) cDNA and polypeptide. (A) The 
nucleotide and predicted amino acid sequences of the mouse PACAP-R cDNA clone pCAPM17. Numbers above and below each lane refer to the 
nncleotide and amino acid positions, respectively. Numbering of the amino acids begins at Met-I of the postulated mature receptor, with negative numbers 
for the signal peptide. The seven putative transmembrane segments are underlined, and the potential N-glycosylation sites in the extracellular region are 
marked by stars. The 84 bp sequence derived from the alternative exon Hop is indicated by undulating lines. (B) Sequences of three other splice variants of 
PACAP-R. The 84 bp sequence derived from the exon Hop can be deleted. It can also be replaced by, or included together with the 84 bp insertion derived 
from the exon Hip. 
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Mouse  
Rat  
Bov ine  
Human 
MRGGRHWPEP I0 
MAGVVHVSLAAHCGACPWGRGRLRKGRAACKSAAQRHIGADLPLLSVGGQ 50  
Mouse  
Rat  
Bov ine  
Human 
MARTLQLSLTALLLLPMAIAMHSDCIFKKEQAMCLERIQRAND 43  
. . .V  . . . . . . . .  ' . . - .V  . . . . . . . . . . . . . . . . . . . . . . . . . .  42  
PCRLRSV. .S IA .V . .A  . . . . . . . .  T . . . . . . . . . . . . . . . . .  K . . .V . .  60  
WCWPRSV. .GVVHV. .A  . . . . . . . .  P . . . . . . . . . . . . . . . . .  K . . . . .  E i00  
Mouse  
Rat  
Bov lne  
Human 
* * 
LMGLNESSPGCPGMWDNIT~PAQIGEMVLVSCPEVFRIFNPDQVWMTE 93  
. . . . . . . . . . . . . . . . . . . . . . . . .  V . . . . . . . . . . . . . . . . . . . . . . . .  92  
. . . . .  D . . . . . . . . . . . . . . . . . .  HV  . . . . . . . . . .  L . . . . . . . . . .  E . .  110  
. . . F .D  . . . . . . . . . . . . . . . . . .  HV  . . . . . . . . . .  L . . . . . . . . . .  E . .  150  
Mouse  
Rat  
























Bov ine  
Human 
* * 
T IGDSGFADSNSLE ITDMGVVGRNCTEDGWSEPF  PHYFDACGFDDYEPES 143  
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  142  
• . .EF  . . . . .  K . .DLS . .R . .S  . . . . . . . . . . . . . . . . . . . . .  EE . .S .T  160  
• . .E .D .G  . . . . .  DLS  . . . . .  S . . . . . . . . . . . . . . . . . . . . . .  E . .S .T  200  
i 
GDQDYYYLSVKALYTVGYSTSLVTLTTAMVI  LCRFRKLHCTRNFIHMNLF  193  
. . . . . . . . . . . . . . . . . . . . . .  A . . . . . . . . . . . . . . . . . . . . . . . . . . .  192  
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  210  
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  250  
II , III 
VSFMLRAI  SVF  IKDWILYAEQDSSHCFVSTVECKAVMVFFHYCVVSNYFW 243 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  242  
. . . . . . . . . . . . . . . . . . . . . . .  N . . . . . . . . . . . . . . . . . . . . . . . . . .  260  
. . . . . . . . . . . . . . . . . . . . . . .  N .  . .I . . . . . . . . . . . . . . . . . . . . . .  300  
IV 
LF  I EGLYLFTLLVETFF  PERRYFYWYTI  IGWGTPTVCVTVWAVLRLYFDD 293 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  292  
. . . . . . . . . . . . . . . . . . . . . . . . . .  I . . . . . . . . . . . .  S. . .M . . . . . . .  310  
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  T . . . . . . .  350  
**  V 
AGCWDMNDSTALWWVI  KGPVVGS IMVNFVLF  IG I  I I I LVQKLQS PDMGGN 343 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  342  
T . . . . . . .  N . . . . . . . . . . . . . . . . . . . . . . . . . .  V . . . . . . . . . . . . . .  360  
T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  V . . . . . . . . . . . . . .  400  
Vl 
ES S I YFSCVQKCYCKPQRAQQHSCKMSELST ITLRLARSTLLL  I PLFG I H 393  
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  392  
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  410  
. . . . .  - . . . . . . . . . . . . . . . . . . . . . . . . . . .  • . . . . . . . . . . . . . . . .  422  
VII 
YTVFAF  S PE IT@S KRERLVFELGLGS FQGFVVAVLYC FLNGEVQAE I KRKW 443 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  442  
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  460  
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  472  
Mouse  
Rat  
Bov ine  
Human 
RSWKVNRYFTMDFKHRHPSLASSGVNGGTQLS ILSKSSSQLRMSSLPADN 493 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  492  
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  I . . .G  . . . . .  510  
. . . . . . . . .  AV  . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  I . . .G  . . . . .  522  
Mouse  LAT  496  
Rat  . . .  495  
Bov ine  . . .  513  
Human . . .  525  
Fig. 2. Amino acid sequence comparison of the PACAP-R of various species. The deduced amino acid sequences of the mouse, rat [9-13], bovine [20], 
and human PACAP-R [21] are aligned. Dots and hyphens indicate identical and deleted amino acids, respectively, compared with those of the mouse. The 
amino acids are numbered from the N-terminus of the precursor protein of each receptor. The seven putative transmembrane segments are indicated by 
bars. In the extracellular region, the cysteine and tryptophan residues conserved among members of this receptor family [9] are marked by stars. 
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Fig. 3. Pharmacological characteristics of the mouse PACAP-R. (A) 
Binding specificity of the mouse PACAP-R. Membrane fractions from 
COS7 cells transfected with the PACAP-R expression plasmid were 
incubated with [1251]PACAP in the presence of various concentrations of 
unlabeled PACAP (Q) and VIP (©). The binding activity obtained in the 
absence of competitors was taken as 100%. The binding assays were 
performed in triplicate, and the average values are plotted. The values 
obtained in triplicate assays agreed within 10% error, (B) Accumulation 
of intracellular cAMP in COS7 cells expressing the mouse PACAP-R. 
COS7 cells transfected with the mouse PACAP-R expression plasmid 
were incubated with various concentrations of PACAP (O) and VIP (©), 
and the cAMP accumulated in the cells was quantified. The assays were 
performed in duplicate, and the average values are plotted. The values in 
duplicate agreed within 5% error. 
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